Matrix Metalloproteinases Are Possible Targets in Monocrotaline-induced Pulmonary Hypertension: Investigation of Anti-remodeling Effects of Alagebrium and Everolimus

Overview

Journal Anatol J Cardiol

Publisher Kare Publishing

Specialty Cardiology & Vascular Diseases

Date 2016 May 17

PMID 27182612

Citations 5

Authors

Ozlem Atli

Sinem Ilgin

Bulent Ergun

Dilek Burukoglu

Ahmet Musmul

Basar Sirmagul

Affiliations

Soon will be listed here.

Abstract

Objective: In our study, sildenafil alone and everolimus or alagebrium in combination with sildenafil were investigated in terms of their additional therapeutic and anti-remodeling activity in monocrotaline-induced pulmonary hypertension (PH) model in rats. In particular, the inter-relationships between PH and matrix metalloproteinases (MMPs) were investigated.

Methods: The pulmonary artery responses of male Sprague Dawley rats were recorded using myography, and the quantities and activities of MMPs were analyzed in homogenates of the pulmonary arteries and lungs by enzyme-linked immunosorbent assays, activity assays, and gelatin zymography techniques.

Results: Our results indicated that the therapeutic effects of sildenafil were accompanied by its suppressor effects on MMP activity. It was also shown that everolimus or alagebrium in combination with sildenafil showed additional regulatory effects on MMPs as well as functional responses on pulmonary artery pressure. Therefore, the enzymes in the MMP superfamily are likely to be target molecules for the treatment of PH.

Conclusion: In conclusion, MMPs were involved in the pathogenesis of PH, and our results suggested that the addition of everolimus or alagebrium to sildenafil therapy may be beneficial in PH. Our results indicated that agents that limit pulmonary vascular hypertrophy and inflammation via their anti-remodeling effects significantly ameliorate mortality and morbidity in PH.

Citing Articles

Searching for Old and New Small-Molecule Protein Kinase Inhibitors as Effective Treatments in Pulmonary Hypertension-A Systematic Review.

Jasinska-Stroschein M, Glajzner P Int J Mol Sci. 2024; 25(23).

PMID: 39684570 PMC: 11641621. DOI: 10.3390/ijms252312858.

Senescence Alterations in Pulmonary Hypertension.

Roger I, Milara J, Belhadj N, Cortijo J Cells. 2021; 10(12).

PMID: 34943963 PMC: 8700581. DOI: 10.3390/cells10123456.

The role of matrix metalloproteinases in patients with pulmonary hypertension: data from a prospective study.

Marc A, Pop C, Sitar-Taut A, Budisan L, Berindan-Neagoe I, Pop D BMC Cardiovasc Disord. 2021; 21(1):607.

PMID: 34930125 PMC: 8686623. DOI: 10.1186/s12872-021-02424-5.

MMP12 knockout prevents weight and muscle loss in tumor-bearing mice.

Jiang L, Yang M, He S, Li Z, Li H, Niu T BMC Cancer. 2021; 21(1):1297.

PMID: 34863141 PMC: 8642861. DOI: 10.1186/s12885-021-09004-y.

Lung tissue remodelling in MCT-induced pulmonary hypertension: a proposal for a novel scoring system and changes in extracellular matrix and fibrosis associated gene expression.

Franz M, Grun K, Betge S, Rohm I, Ndongson-Dongmo B, Bauer R Oncotarget. 2016; 7(49):81241-81254.

PMID: 27835899 PMC: 5348389. DOI: 10.18632/oncotarget.13220.

References

Johnson J, Dwivedi A, Somerville M, George S, Newby A . Matrix metalloproteinase (MMP)-3 activates MMP-9 mediated vascular smooth muscle cell migration and neointima formation in mice. Arterioscler Thromb Vasc Biol. 2011; 31(9):e35-44. DOI: 10.1161/ATVBAHA.111.225623. View

Galis Z, Khatri J . Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res. 2002; 90(3):251-62. View

Karapanagiotidis G, Antonitsis P, Charokopos N, Foroulis C, Anastasiadis K, Rouska E . Serum levels of matrix metalloproteinases -1,-2,-3 and -9 in thoracic aortic diseases and acute myocardial ischemia. J Cardiothorac Surg. 2009; 4:59. PMC: 2774681. DOI: 10.1186/1749-8090-4-59. View

Ahmed S, Clark L, Pennington W, Webb C, Bonnema D, Leonardi A . Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation. 2006; 113(17):2089-96. DOI: 10.1161/CIRCULATIONAHA.105.573865. View

Chen W, Zhong L, Zhang L, Ji X, Zhang M, Zhao Y . Oral rapamycin attenuates inflammation and enhances stability of atherosclerotic plaques in rabbits independent of serum lipid levels. Br J Pharmacol. 2009; 156(6):941-51. PMC: 2697718. DOI: 10.1111/j.1476-5381.2008.00102.x. View

MacLean M, Dempsie Y . The serotonin hypothesis of pulmonary hypertension revisited. Adv Exp Med Biol. 2010; 661:309-22. DOI: 10.1007/978-1-60761-500-2_20. View

Raffetto J, Khalil R . Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem Pharmacol. 2007; 75(2):346-59. PMC: 2254136. DOI: 10.1016/j.bcp.2007.07.004. View

Mam V, Tanbe A, Vitali S, Arons E, Christou H, Khalil R . Impaired vasoconstriction and nitric oxide-mediated relaxation in pulmonary arteries of hypoxia- and monocrotaline-induced pulmonary hypertensive rats. J Pharmacol Exp Ther. 2009; 332(2):455-62. PMC: 2812110. DOI: 10.1124/jpet.109.160119. View

Kuang T, Wang J, Pang B, Huang X, Burg E, Yuan J . Combination of sildenafil and simvastatin ameliorates monocrotaline-induced pulmonary hypertension in rats. Pulm Pharmacol Ther. 2010; 23(5):456-64. PMC: 3108059. DOI: 10.1016/j.pupt.2010.02.003. View

10.

Li X, Wang H, Yang C, Zhang X, Han D, Wang H . Fluoxetine inhibited extracellular matrix of pulmonary artery and inflammation of lungs in monocrotaline-treated rats. Acta Pharmacol Sin. 2011; 32(2):217-22. PMC: 4085716. DOI: 10.1038/aps.2010.187. View

11.

Nishimura T, Faul J, Berry G, Veve I, Pearl R, Kao P . 40-O-(2-hydroxyethyl)-rapamycin attenuates pulmonary arterial hypertension and neointimal formation in rats. Am J Respir Crit Care Med. 2001; 163(2):498-502. DOI: 10.1164/ajrccm.163.2.2006093. View

12.

Campian M, Hardziyenka M, Michel M, Tan H . How valid are animal models to evaluate treatments for pulmonary hypertension?. Naunyn Schmiedebergs Arch Pharmacol. 2006; 373(6):391-400. DOI: 10.1007/s00210-006-0087-9. View

13.

Frisdal E, Gest V, Vieillard-Baron A, LEVAME M, Lepetit H, Eddahibi S . Gelatinase expression in pulmonary arteries during experimental pulmonary hypertension. Eur Respir J. 2002; 18(5):838-45. DOI: 10.1183/09031936.01.00084601. View

14.

Taraseviciene-Stewart L, Scerbavicius R, Stewart J, Gera L, Demura Y, Cool C . Treatment of severe pulmonary hypertension: a bradykinin receptor 2 agonist B9972 causes reduction of pulmonary artery pressure and right ventricular hypertrophy. Peptides. 2005; 26(8):1292-300. DOI: 10.1016/j.peptides.2005.03.050. View

15.

Chu C, Abbara C, Noel-Hudson M, Thomas-Bourgneuf L, Gonin P, Farinotti R . Disposition of everolimus in mdr1a-/1b- mice and after a pre-treatment of lapatinib in Swiss mice. Biochem Pharmacol. 2009; 77(10):1629-34. DOI: 10.1016/j.bcp.2009.02.013. View

16.

Guo Y, Lu M, Qian J, Cheng Y . Alagebrium chloride protects the heart against oxidative stress in aging rats. J Gerontol A Biol Sci Med Sci. 2009; 64(6):629-35. DOI: 10.1093/gerona/glp023. View

17.

Lepetit H, Eddahibi S, Fadel E, Frisdal E, Munaut C, Noel A . Smooth muscle cell matrix metalloproteinases in idiopathic pulmonary arterial hypertension. Eur Respir J. 2005; 25(5):834-42. DOI: 10.1183/09031936.05.00072504. View

18.

Intengan H, Schiffrin E . Structure and mechanical properties of resistance arteries in hypertension: role of adhesion molecules and extracellular matrix determinants. Hypertension. 2000; 36(3):312-8. DOI: 10.1161/01.hyp.36.3.312. View

19.

Kameshima S, Kazama K, Okada M, Yamawaki H . Eukaryotic elongation factor 2 kinase mediates monocrotaline-induced pulmonary arterial hypertension via reactive oxygen species-dependent vascular remodeling. Am J Physiol Heart Circ Physiol. 2015; 308(10):H1298-305. DOI: 10.1152/ajpheart.00864.2014. View

20.

Kiss T, Komocsi A, Tornyos A, Zalan P, Sumegi B, Gallyas Jr F . Novel mechanisms of sildenafil in pulmonary hypertension involving cytokines/chemokines, MAP kinases and Akt. PLoS One. 2014; 9(8):e104890. PMC: 4136836. DOI: 10.1371/journal.pone.0104890. View